Evidence map›Paper›PMID 41379277›Full record

ReviewMedical oncology (Northwood, London, England)2025

Is escalated BEACOPP dead? Rethinking standards in hodgkin lymphoma treatment.

Colette Hanna, Fouad Attieh, Hampig Raphaël Kourie, Fadi G Haddad

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Colette Hanna *Faculty of Medicine, Lebanese American University Medical Center, Rizk Hospital, Zahar Street, 11-3288, Achrafieh, Beirut, Lebanon.
Fouad Attieh *Faculty of Medicine, Saint Joseph University of Beirut, 11-5076, Riad El Solh, 11072180, Beirut, Lebanon. fouad.attieh@net.usj.edu.lb.ORCID http://orcid.org/0000-0002-2599-5521
Hampig Raphaël KourieDepartment of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, 11-5076, Riad El Solh, 11072180, Beirut, Lebanon.ORCID http://orcid.org/0000-0002-2502-5402
Fadi G HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-9702-8485

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escalated BEACOPP has long been a key component in the treatment of Hodgkin lymphoma, offering significant survival benefits in both early and advanced stages. However, its use comes with considerable drawbacks, including heightened toxicity, infertility, and an increased risk of secondary malignancies. The emergence of novel therapies, such as Brentuximab Vedotin-an anti-CD30 antibody-drug conjugate-and immune checkpoint inhibitors like Nivolumab and Pembrolizumab, has begun to redefine the treatment landscape. These advancements provide comparable or superior efficacy while significantly reducing toxicity. This article examines the gradual decline of escalated BEACOPP in Hodgkin lymphoma treatment, highlighting recent clinical trial data and evolving therapy protocols that are shifting treatment paradigms. Additionally, it explores updates in international guidelines reflecting these changes. Despite the promise of newer therapies, their widespread adoption presents challenges, including accessibility, cost, and long-term efficacy considerations. This review discusses these hurdles while looking ahead to future directions in Hodgkin lymphoma management.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHodgkin DiseaseBleomycinCyclophosphamideDoxorubicinEtoposideHumansPrednisoneProcarbazineVincristineBleomycinCyclophosphamideDoxorubicinEtoposidePrednisoneProcarbazineVincristineAntibody-Drug conjugateBrentuximab vedotinEscalated BEACOPPHodgkin lymphomaNivolumab

Identifiers

PMID41379277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.